A single arm, multicenter, open label, phase II study of lapatinib as 2L treatment of pts with locally advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract
Document type:
Meeting Abstract
Author(s):
Wülfing, C; Machiels, JP; Richel, D; Grimm, MO; Treiber, U; de Groot, M; Beuzeboc, P; Farrell, J; Stone, NL; Leopold, L; El-Hariry, I